Updated European Association of Urology Guidelines for Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Clear-cell Renal Cell Carcinoma

Abstract

Cytoreductive nephrectomy (CN) has been the standard of care in patients with metastatic clear cell renal cancer who present with the tumour in place. The CARMENA trial compared systematic therapy alone with CN followed by systemic therapy.

This article outlines the new guidelines based on these data.

Keywords

• Cytoreductive nephrectomy
• EAU guidelines
• Matestatic
• Renal cell cancer
• Sunitinib